The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections to treat several inflammatory conditions. Adults and certain children can receive this medication to treat ...

Basel, October 22, 2025 – Novartis today announced that Cosentyx® (secukinumab) met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial 1. Cosentyx demonstrated ...

New x-ray assessment data, from a sub-study, showed no progression of joint structural damage in the majority of patients with psoriatic arthritis over two years[1] Psoriatic arthritis patients on ...

Novartis has announced that its treatment for polymyalgia rheumatica (PMR), Cosentyx (secukinumab), achieved all primary and secondary endpoints in the phase 3 REPLENISH trial. REPLENISH is a global, ...

The approval was based on data from the phase 3 SUNSHINE and SUNRISE trials, which included 1084 adults with moderate to severe HS. Results showed a significantly greater proportion of patients ...

The FDA has approved an intravenous formulation of Cosentyx for use in patients with psoriatic arthritis, ankylosing spondylitis and nonradiographic axial spondyloarthritis, according to a press ...

The 2025 European Academy of Dermatology and Venereology (2025 EADV), the largest dermatology conference in Europe, opened on the 17th (local time) in Paris, France. Running through the 20th, EADV ...

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. Serious ...

If you take Cosentyx, you already might have discovered that your health insurance might no longer cover the injection used to treat the skin disorder psoriasis. Health-care giant Cigna, which sells ...

(RTTNews) - The U.S. Food and Drug Administration has approved Novartis' (NVS) Cosentyx or secukinumab for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and ...